The New England journal of medicine
-
A diminished number of nephrons has been proposed as one of the factors contributing to the development of primary hypertension. ⋯ The data support the hypothesis that the number of nephrons is reduced in white patients with primary hypertension.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
A controlled trial of natalizumab for relapsing multiple sclerosis.
In patients with multiple sclerosis, inflammatory brain lesions appear to arise from autoimmune responses involving activated lymphocytes and monocytes. The glycoprotein alpha4 integrin is expressed on the surface of these cells and plays a critical part in their adhesion to the vascular endothelium and migration into the parenchyma. Natalizumab is an alpha4 integrin antagonist that reduced the development of brain lesions in experimental models and in a preliminary study of patients with multiple sclerosis. ⋯ In a placebo-controlled trial, treatment with natalizumab led to fewer inflammatory brain lesions and fewer relapses over a six-month period in patients with relapsing multiple sclerosis.